
A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.

A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.

Published: December 2nd 2019 | Updated: